News
DHR
273.91
+1.41%
3.82
Top Stock Reports for Costco, Danaher & ServiceNow
NASDAQ · 5h ago
It's Time for Some Enthusiasm for Small-Cap Stocks
After a year and a half of big names pushing the market forward, some smaller companies are starting to go on a run. The Russell 2000 is up over 10% in the past month. The Magnificent Seven dropped by $1.1 trillion in the last week. This week's Motley Fool Money Radio Show includes a look at the small-cap rally. Also on the show: A restaurant concept and some insights from the CEO of FoolFest 2024.
The Motley Fool · 6h ago
3M (MMM) Q2 Earnings & Revenues Surpass Estimates, Rise Y/Y
NASDAQ · 7h ago
Freeport-McMoRan, Pfizer, Danaher And An Industrial Stock: CNBC's 'Final Trades'
Final Trades: Freeport-McMoRan Inc. And Danaher Corporation. United Rentals posted better-than-expected earnings for its second quarter. Pfizer announced approval of a gene therapy for hemophilia B on July 23. The company also announced a $7.5 billion expansion of its copper mine in Chile.
Benzinga · 12h ago
See Which Of The Latest 13F Filers Holds Danaher
NASDAQ · 1d ago
Beckman Coulter's DxI 9000 Immunoassay Analyzer Honored at Premier, Inc.'s Annual Supplier Innovation Celebration
Beckman Coulter's DxI 9000 Immunoassay Analyzer was honored during Premier, Inc.'s annual supplier Innovation Celebration at its 2024 Breakthroughs Conference and Exhibition. The analyzer has the highest throughput compared to any immunoassays on the market. The system delivers the highest percentage of Six Sigma assays in the world.
PR Newswire · 1d ago
Danaher Price Target Raised to $278.00/Share From $271.00 by Baird
Dow Jones · 2d ago
Danaher Is Maintained at Outperform by Baird
Dow Jones · 2d ago
Baird Maintains Outperform on Danaher, Raises Price Target to $278
Benzinga · 2d ago
Danaher Price Target Raised to $300.00/Share From $297.00 by RBC Capital
Dow Jones · 2d ago
Danaher Is Maintained at Outperform by RBC Capital
Dow Jones · 2d ago
RBC Capital Maintains Outperform on Danaher, Raises Price Target to $300
Benzinga · 2d ago
Danaher Is Maintained at Equal-Weight by Barclays
Dow Jones · 2d ago
Danaher Price Target Raised to $285.00/Share From $270.00 by Barclays
Dow Jones · 2d ago
Barclays Maintains Equal-Weight on Danaher, Raises Price Target to $285
Benzinga · 2d ago
Danaher Is Maintained at Outperform by Leerink Partners
Dow Jones · 2d ago
Danaher Price Target Raised to $280.00/Share From $275.00 by Leerink Partners
Dow Jones · 2d ago
3M (MMM) Stock Before Q2 Earnings: To Buy or Not to Buy?
NASDAQ · 2d ago
Leerink Partners Maintains Outperform on Danaher, Raises Price Target to $280
Benzinga · 2d ago
Demystifying Danaher: Insights From 5 Analyst Reviews
5 analysts have published ratings on Danaher (NYSE:DHR) in the last three months. The company has an average 12-month price target of $269.0. Danaher faces challenges and is expected to see a decline in revenue growth over the next three years. The manufacturer of scientific instruments and consumables has a strong financial position.
Benzinga · 2d ago
More
Webull provides a variety of real-time DHR stock news. You can receive the latest news about Danaher Corporation through multiple platforms. This information may help you make smarter investment decisions.
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three business segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including deoxyribonucleic acid (DNA)and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.